Annovis Bio Enrolls 850 Patients in Landmark Phase 3 Alzheimer's Drug Trial
Buntanetap enters a pivotal Phase 3 trial targeting early Alzheimer's, with results expected as soon as Q1 2027.
Summary
Annovis Bio has finished enrolling 850 patients for a major Phase 3 trial of Buntanetap, an oral drug aimed at early Alzheimer's disease. Patients were confirmed to have Alzheimer's pathology using a blood biomarker called pTau217 and had mild cognitive impairment based on standard memory testing. The trial is randomized, placebo-controlled, and double-blind — the gold standard for clinical research. It will measure both short-term symptom relief at six months and longer-term disease modification at 18 months. If successful, the company plans to file for FDA approval. First results are expected in early 2027, making this one of the most closely watched Alzheimer's drug trials currently underway.
Detailed Summary
Alzheimer's disease remains one of the most urgent challenges in longevity medicine, robbing people of cognitive function and independence in later life. Any drug capable of slowing or reversing its progression would be transformative — not just for patients, but for healthcare systems worldwide. Annovis Bio's Phase 3 trial of Buntanetap is now fully enrolled, marking a significant milestone in the race to find an effective oral therapy.
The trial recruited 850 patients with early Alzheimer's disease across 83 US clinical sites. Crucially, enrollment required confirmation of Alzheimer's pathology via pTau217, a blood-based biomarker increasingly accepted as a reliable indicator of disease. Participants also scored between 20 and 28 on the MMSE, a standard cognitive screening tool, indicating mild but measurable impairment.
Buntanetap is taken as a once-daily oral 30 mg pill — a practical advantage over infusion-based therapies like lecanemab or donanemab. The trial has two pre-specified readouts: a six-month analysis targeting symptomatic improvement and an 18-month analysis targeting disease modification. Primary endpoints measure cognition using ADAS-Cog13 and daily function using ADCS-iADL, both well-validated scales in Alzheimer's research.
Top-line symptomatic data is projected for Q1 2027, with disease-modifying results following in Q1 2028. Annovis has indicated it will pursue separate FDA New Drug Applications following each readout, potentially allowing earlier access if the six-month data is positive.
Caveats are important here. This is a company-issued announcement, not a peer-reviewed publication. Phase 3 trials frequently fail even after promising earlier results. Buntanetap's precise mechanism and prior trial history warrant close scrutiny. Still, the use of a validated biomarker for enrollment and a dual-endpoint design reflects rigorous methodology, and results could meaningfully advance the Alzheimer's treatment landscape.
Key Findings
- 850 patients with pTau217-confirmed early Alzheimer's enrolled across 83 US sites in a Phase 3 trial.
- Buntanetap is an oral daily pill, offering a practical advantage over existing infusion-based Alzheimer's therapies.
- Trial measures both 6-month symptomatic effects and 18-month disease-modifying effects with validated endpoints.
- Top-line symptomatic data expected Q1 2027; disease-modifying data expected Q1 2028.
- Separate FDA NDA submissions planned after each readout, potentially accelerating patient access.
Methodology
This is a corporate news report summarizing a company press release from Annovis Bio, as covered by Longevity.Technology. No peer-reviewed data is presented; the evidence basis is the company's own trial design and enrollment announcement. Independent verification from clinical trial registries such as ClinicalTrials.gov is advisable.
Study Limitations
This article is based solely on a company announcement and has not been independently verified through peer-reviewed publication or regulatory filings. Buntanetap's prior trial history and precise mechanism of action are not detailed, limiting full assessment. Readers should consult ClinicalTrials.gov and published literature for complete context before drawing conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: